Anticancer TLR agonists on the ropes
Nature Reviews Drug Discovery 11,503 (2012).
doi:10.1038/nrd3775
Author:Malini Guha
Toll-like receptor agonists have hit another setback with the Phase II failure of Idera’s IMO-2055,but these immunotherapies may still make a comeback if appropriate combinations with vaccine antigens or anticancer drugs can be identified.
Nature Reviews Drug Discovery –Issue –nature.com science feeds












































